FACTORS INFLUENCING CONFORMITY INDEX IN RADIOTHERAPY FOR NON SMALL CELL LUNG CANCER

被引:10
|
作者
Brennan, Sinead M. [1 ]
Thirion, Pierre
Buckney, Steve
Shea, Carmel O.
Armstrong, John
机构
[1] St Lukes Hosp, Dept Radiat Oncol, Clin Trials Unit, Dublin 6, Ireland
关键词
Lung cancer; Radiotherapy; Conformity index; THERAPY ONCOLOGY GROUP; RADIATION-THERAPY; QUALITY-ASSURANCE; RADIOSURGERY; VOLUME;
D O I
10.1016/j.meddos.2009.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The radiotherapy conformity index (CI) is a useful tool to quantitatively assess the quality of radiotherapy treatment plans, and represents the relationship between isodose distributions and target volume. A conformity index of unity implies high planning target volume (PTV) coverage and minimal unnecessary irradiation of surrounding tissues. We performed this analysis to describe the CI for lung cancer 3-dimensional conformal radiotherapy (3DCRT) and to identify clinical and technical determinants of CI, as it is not known which factors are associated with good quality 3D conformal radiotherapy treatment planning. Radiotherapy treatment plans from a database of 52 patients with inoperable Stage 1 to 3b lung cancer, on a hypofractionated 3DCRT trial were evaluated. A CI was calculated for all plans using the definition of the ICRU 62:CI = (TV/PTV), which is the quotient of the treated volume (TV) and the PTV. Data on patient, tumor, and planning variables, which could influence CI, were recorded and analyzed. Mean CI was 2.01 (range = 1.06-3.8). On univariate analysis, PTV (p = 0.023), number of beams (p = 0.036), medial vs. lateral tumor location (p = 0.016), and increasing tumor stage (p = 0.041) were associated with improved conformity. On multiple regression analysis, factors found to be associated with CI included central vs. peripheral tumor location (p = 0.041) and PTV size (p = 0.058). The term 3DCRT is used routinely in the literature, without any indication of the degree of conformality. We recommend routine reporting of conformity indices. Conformity indices may be affected by both planning variables and tumor factors. (C) 2010 American Association of Medical Dosimetrists.
引用
收藏
页码:38 / 42
页数:5
相关论文
共 50 条
  • [21] High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer
    Allena, Aaron M.
    Shochat, Tzippy
    Flex, Dov
    Kramer, Mordechai R.
    Zer, Alona
    Peled, Nir
    Dudnik, Elizabeta
    Fenig, Eyal
    Saute, Milton
    ONCOLOGY, 2018, 95 (01) : 13 - 19
  • [22] Is stereotactic body radiotherapy an alternative to surgery in early stage non small cell lung cancer?
    Yaprak, Gokhan
    Seseogullari, Ozgur Ozan
    Akaslan, Bedriye Dogan
    Isik, Naciye
    JOURNAL OF BUON, 2019, 24 (04): : 1619 - 1625
  • [23] Definitive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Dose and Fractionation
    Dagoglu, Nergiz
    Karaman, Sule
    Arifoglu, Alptekin
    Kucucuk, Seden
    Oral, Ethem N.
    BALKAN MEDICAL JOURNAL, 2014, 31 (04) : 278 - 285
  • [24] The Current Role of Radiotherapy in the Treatment of Small Cell Lung Cancer
    Woolf, D. K.
    Slotman, B. J.
    Faivre-Finn, C.
    CLINICAL ONCOLOGY, 2016, 28 (11) : 712 - 719
  • [25] Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer
    Nieder, Carsten
    Imingen, Kristian S.
    Mannsaker, Bard
    Yobuta, Rosalba
    Haukland, Ellinor
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [26] Hypofractionated Radiotherapy in Non Small Cell Lung Cancer: A Review of the Current Literature
    Beli, I
    Koukourakis, G.
    Platoni, K.
    Tolia, M.
    Kelekis, N.
    Kouvaris, J.
    Syrigos, C.
    Mystakidou, K.
    Varveris, C.
    Kouloulias, V
    REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (02) : 103 - 111
  • [27] Advances in palliative radiotherapy of metastatic non-small cell lung cancer
    Kapoor, Rakesh
    Simha, Vijai
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (04) : 397 - 402
  • [28] Motion Management for Radical Radiotherapy in Non-small Cell Lung Cancer
    Cole, A. J.
    Hanna, G. G.
    Jain, S.
    O'Sullivan, J. M.
    CLINICAL ONCOLOGY, 2014, 26 (02) : 67 - 80
  • [29] Postoperative radiotherapy in non-small cell lung cancer
    Roelandts, M.
    Moretti, L.
    Van Houtte, P.
    CANCER RADIOTHERAPIE, 2011, 15 (6-7): : 514 - 517
  • [30] Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer
    Carsten Nieder
    Kristian S. Imingen
    Bård Mannsåker
    Rosalba Yobuta
    Ellinor Haukland
    Radiation Oncology, 15